Can Olaparib treat breast cancer?

When used to treat metastatic breast cancer, a difference between olaparib and chemotherapy treatments was noted at 2 months. Lynparza delayed disease progression by 7 months compared with 4.2 months in patients treated with chemotherapy. People who received olaparib were 42% less likely to have their cancer grow or spread than those who received chemotherapy. Additionally, 52% of people saw their tumors shrink, compared with 23% of people who received certain chemotherapy treatments. Kaplan-Meier plots of 1,836 patients with germline BRCA-mutated HER2-negative high-risk early breast cancer from the Olympia RCT showing differences in invasive disease-free survival between patients who received olaparib and those who received placebo over several months during the trial (60 months).